Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  Fosgonimeton (ATH-1017)

Research reference — not for sale

Fosgonimeton (ATH-1017)

F

lead outcome

Alzheimer's disease (the lead use)

grades vary by outcome ↓

Small molecule (non-peptide)

also called — Fosgonimeton · ATH-1017 · NDX-1017 (earlier code)

neurodegeneration (Alzheimer's — failed)HGF/MET modulationneuroprotection (hypothesized)cognition (unproven)

The rigorous clinical debunk of the "boost brain growth factors" idea — with a data-fraud scandal attached. Fosgonimeton finishes a story the register started at Dihexa (#44): it targets the same HGF/c-Met pathway, but unlike Dihexa (retracted for fabrication), it was actually taken to Phase 2/3 in Alzheimer's — and failed honestly. Two big stories: (1) the scientific debunk — the hypothesis that "positively modulating HGF/growth-factor signaling treats neurodegeneration" was tested rigorously and did not beat placebo; (2) the corporate drama — Athira's program was already shadowed by a data-manipulation scandal (its CEO ousted over altered images) and an activist proxy fight before the pivotal trial flopped. It's a small molecule, not a peptide.

In brief

Fosgonimeton (ATH-1017) is a small-molecule positive modulator of the HGF/MET system — the growth-factor pathway that's reduced in the Alzheimer's brain — developed by Athira Pharma as a once-daily injection for Alzheimer's. It matters to this register because it completes the story begun at Dihexa (#44): both target the same HGF/c-Met "brain growth factor" axis, but where Dihexa collapsed under retracted, fabricated data, fosgonimeton was taken all the way to a pivotal Phase 2/3 trial (LIFT-AD) — and honestly failed, missing its primary and key secondary endpoints (cognition and function no better than placebo). That's the rigorous debunk of the "enhance growth-factor signaling to treat neurodegeneration" hypothesis. The drama runs deeper: Athira's founding science was already tainted by a data-manipulation scandal (its CEO ousted over altered images) and an activist proxy fight, and after the failure the company clung to post-hoc subgroups while executives spun the miss as "encouraging." The honest read: a safe, well-tolerated drug for a compelling-sounding mechanism that, tested properly, did not help Alzheimer's patients — a clinical debunk wrapped in a research-integrity cautionary tale. Safety wasn't the problem; efficacy was.

Legal standing, by region

United States

Not approved

not approved for any indication; its lead Alzheimer's program failed Phase 2/3 (2024). Investigational; the pathway continues only in a separate ALS candidate (ATH-1105).

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Alzheimer's disease (the lead use)

Tested and failed at pivotal scale — cognition/function no better than placebo (P≈0.70). Not "untested" — clearly negative

Phase 2/3 LIFT-AD: missed primary (GST) + key secondaries; ACT-AD Ph2 missed; earlier failures

F

Parkinson's / Lewy-body dementia

Underpowered, failed; subgroup grasping

SHAPE cut 75→28 patients, missed primary; "5-patient subgroup"

F

Subgroup "signals" (APOE4, monotherapy, advanced disease)

Classic post-hoc rescue; hypothesis-generating at best, not evidence of efficacy

Post-hoc / prespecified subgroups after failed primaries

D

HGF/MET mechanism (as biology)

The biology is legitimate; it didn't translate to clinical benefit — the whole point

Real: MET signaling diminished in AD hippocampus; neuroprotective in models

C

Safety

Consistently safe and well-tolerated — its failure was efficacy, not safety

Phase 1–3 exposure

B

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Fosgonimeton (ATH-1017) changes - nothing else.

Identity

a synthetic small molecule designed to enhance signaling through the HGF/MET (c-Met) system — the hepatocyte-growth-factor pathway that promotes neuronal survival and synaptic function, and which is diminished in the Alzheimer's hippocampus. Given as a once-daily subcutaneous injection, it was Athira Pharma's lead candidate for Alzheimer's disease (and tested in Parkinson's/Lewy-body dementia). It is the clinically-developed cousin of Dihexa (#44), which targets the same HGF/c-Met axis.

Mechanism (as proposed)

HGF (hepatocyte growth factor) and its receptor MET (c-Met) form a signaling system that supports neuronal survival, synaptic function, and repair; MET expression is reduced in the Alzheimer's hippocampus, which motivated the idea that positively modulating HGF/MET could be neuroprotective and disease-modifying. Fosgonimeton was designed to enhance this signaling (improving synaptic function and protecting neurons). The mechanism is biologically reasonable and shares its target with Dihexa (#44) — but LIFT-AD is the decisive data point: enhancing HGF/MET signaling, at the tested dose and duration, did not slow cognitive or functional decline in mild-to-moderate Alzheimer's. It's a textbook reminder that a plausible, well-supported mechanism is a hypothesis, not a result — and that the only way to know is an adequately powered trial, which here returned a clear negative.

Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

CAS2093305-05-4

PubChem CID156596375

InChIKeyMBYDCPOKVKDSFD-JTJYXVOQSA-N

SMILESCCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(=O)N

UNIIH91OA9858J

ChEMBLCHEMBL5095419

via PubChem exact-name match (Fosgonimeton) · high confidence

Sources — 4 cited

01LIFT-AD Phase 2/3 (NCT04488419) topline, Sept 2024: missed primary (GST combining ADAS-Cog11 + ADCS-ADL23) and key secondaries; GST ≈ −0.08, P ≈ 0.70; APOE4 subgroup signal (CTAD 2024).

02ACT-AD Phase 2 (NCT04491006) — missed primary, monotherapy P300 hint; SHAPE (NCT04831281, PDD/DLB) — enrollment cut 75→28, missed.

03Hua X, et al. Safety, Tolerability, PK/PD of the HGF/MET Positive Modulator Fosgonimeton… J Alzheimers Dis. 2022;86(3):1399-1413 (Phase 1); ALZFORUM fosgonimeton entry (MET reduced in AD hippocampus; pivot to ATH-1105 for ALS).

04STAT News (Sept 2024): trial failure "marred by a data manipulation scandal" (CEO altered images, ousted); FierceBiotech: activist proxy fight, post-hoc subgroup reliance. (Not approved; Alzheimer's program failed as of 2026.)

Updated 2026-07-13 (Alzheimer's program failed/effectively discontinued; the HGF/MET pathway continues only via oral ATH-1105 in ALS — the remaining test of whether the mechanism helps any neurodegenerative disease)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

Dihexa (PNB-0408)F

AOD-9604 (hGH fragment 176-191 analog)F

Adipotide (FTPP / Prohibitin-TP01)F

Larazotide (AT-1001, Larazotide Acetate)D

Explore by goal

Neuro & cognitive →

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data Brands

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.